Trial · NCT07905924
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
NCT07905924, Phase 1, Not yet recruiting, Hoffmann-La Roche
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation. Trials, record NCT07905924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905924
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
- NCT number
- NCT07905924
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 540 participants, estimated
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Solid Tumors
- Interventions
- RO7836748, Pembrolizumab, mFOLFIRINOX, Cetuximab
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Parts 1A and 1B: Incidence and Severity of Adverse Events (AEs) | From first dose up to approximately 5 years | |
| Primary | Part 2: Incidence and Severity of AEs | From first dose up to approximately 5 years | |
| Primary | Parts 3A, 3B and 3C: Incidence and Severity of AEs | From first dose up to approximately 5 years | |
| Primary | Parts 1A and 1B: Incidence of Dose-limiting Toxicities (DLTs) | From Cycle 1 Day 1 (C1D1) until C1D21 (Cycle 1 = 21 days) | |
| Primary | Part 3A: Incidence of DLTs | From C1D1 until C1D21 (Cycle 1 = 21 days) | |
| Primary | Parts 3B and 3C: Incidence of DLTs | From C1D1 until C1D28 (Cycle 1 = 28 days) | |
| Primary | Parts 1A and 1B: Recommended Dose for Expansion (RDE) of RO7836748 Monotherapy | Up to approximately 5 years | |
| Primary | Parts 3A, 3B, 3C: RDE of RO7836748 in Combination With Other Anti-Cancer Therapies | Up to approximately 5 years | |
| Secondary | Parts 1A, 1B and 2: Plasma Concentrations of RO7836748 and its Metabolites as Monotherapy | Up to approximately 5 years | |
| Secondary | Parts 3A, 3B and 3C: Plasma Concentrations of RO7836748 and its Metabolites in Combination With Other Anti-Cancer Therapies. | Up to approximately 5 years |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905924
GET https://conductscience.org/api/trials/v1/NCT07905924/registered